Arca
Skip to content
Tools
Tools

Non-cystic fibrosis bronchiectasis

Drug research and approvals for non-cystic fibrosis bronchiectasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 24 studies of non-cystic fibrosis bronchiectasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 24
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 24 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 10, 2026A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose range finding study to evaluate the efficacy, safety, and…CSL787CSLPending
Mar 20, 2026A randomized, double-blinded, placebo-controlled, parallel-group, phase 2a participants with non-cystic fibrosis bronchiectasis (NCFB) study to assess the…SAR445399Sanofi-Aventis Canada IncOngoing
Feb 28, 2024A randomized, double-blind, placebo-controlled, parallel group, proof-ofconcept (POC) study to assess the efficacy, safety and tolerability of itepekimab, in…Itepekimab (SAR440340; REGN3500)Sanofi-Aventis Canada IncClosed
Feb 4, 2021A multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week, phase III study with an open-label extension to evaluate the efficacy and…Benralizumab (MEDI-563)AstraZeneca PharmaceuticalsOngoing
Dec 3, 2020A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of brensocatib administered once daily for 52…Brensocatib (INS1007)InsmedClosed
Jan 31, 2018A double-blind, placebo controlled, multi-center, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled promixin®…ColistimethateZambonClosed
Apr 17, 2014A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pulmaquin® in the management of chronic lung…PulmaquinAradigmClosed
Mar 7, 2014A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pulmaquin® in the management of chronic lung…PulmaquinAradigmClosed

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Nov 18, 2025BrinsupriBrensocatibInsmed Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.